ArticleCureus2024
Impact of Antimicrobial Therapy on Mortality and Readmission in Multidrug-Resistant Pseudomonas Infections: A Retrospective Study at Dammam Medical Complex.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Indian Society of Critical Care Medicine Guidelines on Evidence-based Recommendations for the Treatment of Carbapenem-resistant Enterobacterales, Carbapenem-resistantIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) Pseudomonas aeruginosa presents a significant treatment challenge, necessitating effective antimicrobial options. This retrospective, single-center cohort study was conducted at Dammam Medical Complex and aimed to evaluate the comparative effectiveness and safety of ceftazidime-avibactam (CAZ-AVI), ceftolozane-tazobactam (C-T), and meropenem and colistin in treating MDR P. aeruginosa infections. The study included 250 patients (n = 250, 100%) admitted between January 2022 and November 2024, who were treated with one of the three antimicrobials. The primary outcomes assessed were clinical cure, 30-day mortality, and all-cause in-hospital mortality. Secondary outcomes included readmission rates within 30 days and the rate of uncontrolled infection by day 14 (n = 40, 16%). The patient cohort consisted of a mix of ICU admissions (n = 138, 55.2%), mechanically ventilated patients (n = 140, 56%), and those requiring vasopressors (n = 100, 40%). Most patients were elderly with multiple pre-existing medical conditions, such as diabetes (n = 175, 70%), hypertension (n = 88, 35.2%), and chronic kidney disease (n = 63, 25.2%). Results demonstrated that ceftazidime-avibactam was associated with a statistically significant higher clinical cure rate (n = 180, 72%) compared to ceftolozane-tazobactam (n = 44, 59%) and meropenem and colistin (n = 24, 48%) (P < 0.05). Similarly, patients treated with CAZ-AVI had significantly lower readmission rates within 30 days compared to those on C-T or meropenem and colistin. The overall in-hospital mortality was highest among patients treated with meropenem and colistin (n = 19, 38%), followed by C-T (n = 24, 32%), and lowest with CAZ-AVI (n = 30, 24%) (P < 0.05). The findings suggest that ceftazidime-avibactam is more effective in achieving clinical cure and reducing readmission rates compared to ceftolozane-tazobactam and meropenem and colistin in patients with MDR P. aeruginosa infections. Meropenem and colistin were primarily used when supply constraints limited the availability of other agents, highlighting the need for improved access to preferred antimicrobials. These results underscore the importance of optimized antimicrobial stewardship in the management of MDR P. aeruginosa to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.